NeoGenomics, Inc. (NEO) is a publicly traded Healthcare sector company. As of August 24, 2026, NEO trades at $17.05 with a market cap of $2.18B and a P/E ratio of 0.00. NEO moved +0.41% today. Year to date, NEO is +44.39%; over the trailing twelve months it is +174.76%. Its 52-week range spans $4.72 to $19.12. Analyst consensus is buy with an average price target of $17.80. Rallies surfaces NEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for NEO, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $17.05 |
| Market Cap | $2.18B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.12 |
| 52-Week Low | $4.72 |
| Volume | 266 |
| Avg Volume | 0 |
| Revenue (TTM) | $727.33M |
| Net Income | $-108.03M |
| Gross Margin | 43.21% |
7 analysts cover NEO: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $17.80.